INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01Kurtz George0B / 204S204 trades$51.20M
  2. 02SPSaba Capital Management, L.P.70B / 21S · 11 late91 trades$26.34M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 33S33 trades$5.33M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  7. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  8. SELLULCCFrontier Group Holdings, Inc.Nov 5 – Nov 117 insiders$1.31M

Form 4 transactions

68,650 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
BJ
Batdorff Douglas J.SVP, Manufacturing Operations
KEQUKEWAUNEE SCIENTIFIC CORP /DE/
Grant or award
A—
2,717 sh
Jun 24, 2026
Page 618 of 1717
← PrevNext →
Jun 25, 2026
traded Jun 24, 2026
+1d
SEC Form 4

Evidence

7
AI
Alclear Investments, LLCDirector, 10% Owner, See Remarks
YOUClear Secure, Inc.
Grant or award · 10b5-1 plan
A—
196.6K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC Form 4

Evidence

7
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$136K
15.6K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC Form 4

Evidence

7
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$97K
13.3K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC Form 4

Evidence

6
BD
Brown Christopher D.Director
MASS908 Devices Inc.
Open-market sale · 10b5-1 plan
SELL$89K
9,900 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
GJ
Garnett Timothy JohnDirector
MPLTMapLight Therapeutics, Inc.
Grant or award
A—
14.9K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
LA
Leggett Michael AdamSr VP & Chief Supply Chain Off
LZBLA-Z-BOY INC
Tax withholding
F$21K
526 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
ML
McCurry Jennifer LynnChief Accounting Officer
LZBLA-Z-BOY INC
Tax withholding
F$8,100
201 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
HD
Hull Thomas David IiiDirector, President & CEO
KEQUKEWAUNEE SCIENTIFIC CORP /DE/
Grant or award
A—
15.2K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

5
CM
Coetzee MichaelVP and GM Fuel Syst. Americas
PHINPHINIA INC.
Grant or award
A—
33 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
FN
Fryer NeilVP and GM Global Aftermarket
PHINPHINIA INC.
Grant or award
A—
34 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
MA
Mendelsohn AaronDirector
VANIVivani Medical, Inc.
Grant or award
A$45K
36.5K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

5
YH
Yang HongyongVP and GM Fuel Syst. Asia Pac
PHINPHINIA INC.
Grant or award
A—
4 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
WG
Williams GreggDirector, 10% Owner
VANIVivani Medical, Inc.
Grant or award
A$45K
36.5K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

5
CJ
Cordella Richard James JRDirector
MVBFMVB FINANCIAL CORP
Option exercise
M—
3,701 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
VG
Vasquez Alison GautEVP AND CFO
ORNOrion Group Holdings Inc
Tax withholding
F$36K
2,325 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
GC
Gustanski ChristopherVP, Operational Excellence
PHINPHINIA INC.
Grant or award
A—
25 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
VD
Vidal DanielDirector
EXFYExpensify, Inc.
Grant or award
A—
1.16M sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
GT
Gardner Donald T. IIIChief Financial Officer
KEQUKEWAUNEE SCIENTIFIC CORP /DE/
Grant or award
A—
5,428 sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

5
PS
Pombier SamanthaVice President and Controller
PHINPHINIA INC.
Grant or award
A—
11 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
SR
Schaffer RyanDirector, Chief Financial Officer
EXFYExpensify, Inc.
Grant or award
A—
1.16M sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
MF
Mills Jason FahrDirector
EXFYExpensify, Inc.
Grant or award
A—
1.16M sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

5
BJ
Bisharat JalehDirector
WLTHWEALTHFRONT CORP
Grant or award
A—
19.4K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

4
SM
Schlosser MarioDirector
OSCROscar Health, Inc.
Derivative conversion · 10b5-1 plan
C—
880.0K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

4
SM
Schlosser MarioDirector
OSCROscar Health, Inc.
Derivative conversion · 10b5-1 plan
C—
880.0K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

3
BS
Bizily ScottChief Legal Officer
FDMT4D Molecular Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
9,810 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

2
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Grant or award
A—
2.09M sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

1
SM
Schlosser MarioDirector
OSCROscar Health, Inc.
Open-market sale · 10b5-1 plan
SELL$54K
1,799 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

0
SM
Schlosser MarioDirector
OSCROscar Health, Inc.
Derivative conversion · 10b5-1 plan
C—
50.0K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

0
DM
Doyle MittieChief Medical Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$12K
1,450 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

0
AI
Alclear Investments, LLCDirector, 10% Owner, See Remarks
YOUClear Secure, Inc.
Grant or award · 10b5-1 plan
A—
16.0K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

0
IN
Intrator Michael NDirector, CEO and President, 10% Owner
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
107.7K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

0
AI
Alclear Investments, LLCDirector, 10% Owner, See Remarks
YOUClear Secure, Inc.
Disposition to issuer · 10b5-1 plan
D—
16.0K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

0
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
13.3K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC Form 4

Evidence

0
Silbermann BenjaminDirector, 10% Owner
PINSPINTEREST, INC.
Derivative conversion · 10b5-1 plan
C—
0 sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

0
AI
Alclear Investments, LLCDirector, 10% Owner, See Remarks
YOUClear Secure, Inc.
Grant or award · 10b5-1 plan
A—
16.0K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

0
AI
Alclear Investments, LLCDirector, 10% Owner, See Remarks
YOUClear Secure, Inc.
Disposition to issuer · 10b5-1 plan
D—
196.6K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC Form 4

Evidence

0
Silbermann BenjaminDirector, 10% Owner
PINSPINTEREST, INC.
Derivative conversion · 10b5-1 plan
C—
0 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence

0
Silbermann BenjaminDirector, 10% Owner
PINSPINTEREST, INC.
Derivative conversion · 10b5-1 plan
C—
46.9K sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC Form 4

Evidence

0
DM
Doyle MittieChief Medical Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
1,450 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC Form 4

Evidence